secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2024-03-19T23:59:59+00:00
Accession:  0000950170-24-033159
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya Therapeutics reports FY2023 net loss of $8.0M; cash $32.6M plus $7.5M upfront from Dr. Reddy's
--------------------------------------------------------------------------------

- Net loss improved to $8.0M in FY2023 from $12.2M in FY2022; R&D spend $5.5M, G&A $7.8M.
- Cash and equivalents $32.6M at Dec 31, 2023; plus $7.5M upfront from Dr. Reddy's received Jan 2024.
- Closed Jan 2023 IPO net $14.1M and Dec 2023 private placement net $24.0M.
- Dr. Reddy's collaboration for COYA 302 in ALS: up to $733M milestones plus low-to-mid teens royalties.
- IND for COYA 302 in ALS expected 2Q24; Ph.2 topline data targeted for 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000095017024033159/0000950170-24-033159-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000095017024033159/coya-20240319.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-033159

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer